AI can rapidly generate new protein binders, but wet-lab validation remains a major bottleneck. Combining cell-free protein synthesis with surface plasmon resonance (SPR) enables AI-designed antibody binders to be screened directly from crude extracts, bypassing lengthy cell culture and purification steps.
As genomic studies become larger and more diverse, sample collection can make or break their success. Discover why collection strategy matters for recruitment, scale and data quality.
What happens when the cellular machinery making therapeutic proteins slows down? New research in Nature shows why translation speed could matter for the design of mRNA medicines.
Human biospecimens can bring drug discovery closer to human disease, but their value depends on far more than the sample itself. We explore the factors that determine how much researchers can learn from them.
Humanised antibodies targeting the voltage-gated sodium channel Nav1.7 have demonstrated prolonged suppression of neuropathic pain in a rat model.
A bacterial enzyme produced by Bacteroides vulgatus has been shown to inactivate the intestinal hormone GLP-2, disrupting gut barrier function and aggravating colitis in a preclinical model — with a natural product inhibitor identified as a potential intervention.
Scientists at the Salk Institute have constructed a comprehensive atlas of previously uncharacterised microproteins in the human frontal cortex, identifying over 1,000 novel candidates.
A nasal spray using extracellular vesicles derived from the amniotic membrane has shown promise against Alzheimer’s disease, reducing neuroinflammation, protecting neuronal function and preserving memory in experimental models.
What can pooled CRISPR screening and protein‑level readouts reveal that transcriptomics alone can’t? Explore how single‑cell genomic perturbations, intracellular protein measurements and surface‑protein profiling expose signalling pathways and clarify antibody specificity.
Five leading cancer researchers from across genomics, proteomics, cell biology, chemical biology and gene therapy dig into what’s driving cancer drug discovery forward and what’s still holding progress back.
Non-animal methods are already used throughout early drug discovery, yet animal testing continues to dominate regulatory safety assessment. Recent initiatives suggest change is coming, but significant scientific and practical challenges remain.